RxDoctor Payments Data

Jeffrey Steed, PA

Physician Assistant · Pomona, CANPI 1932730884

Payments from drug & device makers

$19,976in general payments, 2019–2025

Across 841 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$2K
  • Astellas Pharma US Inc$998
  • Pfizer$965
  • E.r. Squibb & Sons, L.L.C.$890
  • Incyte Corporation$820
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$16,28882%
  • Education$1,5068%
  • Other$2,18111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis97$3,293
Johnson & Johnson96$2,052
Astellas Pharma US Inc31$998
Pfizer52$965
E.r. Squibb & Sons, L.L.C.47$890
Incyte Corporation34$820
Merck34$726
Bristol Myers Squibb34$694
Bayer28$654
AstraZeneca(2 entities)31$652
Takeda Pharmaceuticals U.S.A., Inc.19$602
Gilead17$592
Pharmacyclics LLC, An Abbvie Company20$506
Amgen20$466
Seagen Inc.20$462
Daiichi Sankyo Inc.22$433
Eisai Inc.20$422
Sanofi17$345
GSK19$339
Pharmaessentia USA Corporation12$268
Karyopharm Therapeutics Inc.11$255
Lilly USA, LLC15$225
Beigene USA, Inc.7$200
Rigel Pharmaceuticals, Inc.8$199
Jazz Pharmaceuticals Inc.3$195
Taiho Oncology, Inc.7$171
Puma Biotechnology, Inc.7$170
EMD Serono, Inc.6$156
Regeneron Healthcare Solutions, Inc.6$155
Exelixis Inc.7$152
Sobi, Inc5$147
AbbVie6$147
GE HealthCare7$137
Boehringer Ingelheim7$118
Blueprint Medicines Corporation4$101
Dova Pharmaceuticals5$98
Deciphera Pharmaceuticals Inc.5$93
Sumitomo Pharma America, Inc.4$75
Array Biopharma Inc5$73
Genentech USA, Inc.3$69
ADC Therapeutics America, Inc.3$68
Boston Scientific1$60
Stemline Therapeutics Inc.3$57
Ipsen Biopharmaceuticals, Inc3$56
Progenics Pharmaceuticals, Inc.3$50
Global Blood Therapeutics, Inc.3$48
Kyowa Kirin, Inc.2$47
Pharmacosmos Therapeutics Inc.2$42
Myovant Sciences Inc.2$40
Morphosys, US Inc.2$40
Mirati Therapeutics, Inc.2$39
AVEO Pharmaceuticals, Inc.2$39
CSL Behring1$30
Foundation Medicine, Inc.2$29
Immunogen, Inc.1$29
Sun Pharmaceutical Industries Inc.1$25
Tersera Therapeutics LLC1$24
Agios Pharmaceuticals, Inc.1$20
Novocure Inc.1$19
G1 Therapeutics, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,976 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$9,785
Medicare patients
77
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib25$389,717
NinlaroIxazomib Citrate12$153,879
Abiraterone Acetate25$99,863
OrgovyxRelugolix12$29,731
EliquisApixaban25$14,053
Letrozole27$419
Anastrozole18$292
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$247
Hydroxyurea15$206
Ondansetron Hcl22$90
Methylprednisolone15$66
Alendronate Sodium13$60
Prednisone28$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$965$403,77050 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$602$153,87912 claims
Sumitomo Pharma America, Inc.Orgovyx$75$29,73112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Pomona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →